Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05156866 · ClinicalTrials.gov registry record · Phase 1
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
A Phase 1 study of Advanced Solid Tumor and Gastric Cancer, sponsored by TORL Biotherapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 163
- Enrollment target
- 12
- Study locations
NCT05156866: Active Phase 1 study of Advanced Solid Tumor and Gastric Cancer, sponsored by TORL Biotherapeutics.
NCT05156866 is a Phase 1 study of Advanced Solid Tumor and Gastric Cancer that is active but no longer recruiting, run by TORL Biotherapeutics. The registered enrollment target is 163 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (15% lower). The trial reports 12 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05156866, a Phase 1 study of Advanced Solid Tumor and Gastric Cancer, is active but no longer recruiting, sponsored by TORL Biotherapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 163 participants
- Enrollment target
- 12
- Study locations
Study Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer
Primary Outcome
Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0
Conditions Studied
Interventions
- DRUG TORL-2-307-ADC
Study Locations (12)
Texas
- Texas Oncology-Austin - Austin
- Texas Oncology-Dallas - Dallas
- START San Antonio - San Antonio
- Texas Oncology-Tyler - Tyler
California
- Providence St. Jude Medical Center - Fullerton
- UCLA - JCCC Clinical Research Unit - Los Angeles
- Torrance Memorial Medical - Torrance
Other
- Seoul National University Hospital - Seoul
- Severance Hospital, Yonsei University Health System - Seoul
- Seoul National University Bundang Hospital - Seoul
Indiana
- Fort Wayne Medical Oncology and Hematology - Fort Wayne
Missouri
- Washington University School of Medicine-Siteman Cancer Center - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2022-02-02 |
| Est. Completion | 2027-02-15 |
| Phase | Phase 1 |
What the registry record for NCT05156866 still lists
NCT05156866 is an interventional study that assigns participants to a tested intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (15% lower).
The record links to 4 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which TORL-2-307-ADC is the first listed.
NCT05156866 lists 12 locations in 5 states (Texas, California, Other).
Frequently Asked Questions
What is clinical trial NCT05156866 about?
NCT05156866 is a clinical study titled "First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer". This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer
What is the current status of trial NCT05156866?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 163 participants. The study started on 2022-02-02. Estimated completion is 2027-02-15.
What conditions does trial NCT05156866 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma.
What interventions are being tested in trial NCT05156866?
The interventions under investigation include: TORL-2-307-ADC (DRUG).
Who is sponsoring clinical trial NCT05156866?
This trial is sponsored by TORL Biotherapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05156866 being conducted?
This trial has 12 study locations across California, Indiana, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05156866's enrollment target sits among peer trials
163 77th of 189 higher than 113 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT05702229 · 163 participants · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI